SVB Wealth LLC recently announced the acquisition of new stake in Finch Therapeutics Group Inc. (NASDAQ:FNCH). This fresh investment now brings its stake to 0.53% valued currently at $0.12 million.
With over 1.14 million Finch Therapeutics Group Inc. (FNCH) shares trading Tuesday and a closing price of $0.49 on the day, the dollar volume was approximately $0.56 million. The shares have shown a negative half year performance of -75.01% and its price on 01/24/23 lost nearly -1.34%. Currently, there are 47.73M common shares owned by the public and among those 23.40M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for FNCH have a consensus price objective of $15.00. The analysts have set the share’s price value over the next 12 months at a high of $17.00 and a low of $13.00. The average price target is 96.08% above its recent price level and an upside to the estimated low will see the stock gain 96.23% over that period. But an upside of 97.12% will see the stock hit the forecast high price target while median target price for the stock is $15.00.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 70,000 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 7,272 shares.
The top 3 mutual fund holders in Finch Therapeutics Group Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Aperture Investors SICAV – Endeav. Vanguard Total Stock Market Index owns 0.86 million shares of the company’s stock, all valued at over $0.41 million. Vanguard Extended Market Index Fu bought 470.0 shares to see its total holdings expand to 0.12 million shares valued at over $58064.0 and representing 0.25% of the shares outstanding. Aperture Investors SICAV – Endeav sold 58099.0 shares to bring its total holdings to over 0.12 million shares at a value of $57000.0. Aperture Investors SICAV – Endeav now owns shares totaling to 0.25% of the shares outstanding.
Shares of Finch Therapeutics Group Inc. (NASDAQ: FNCH) opened at $0.56, up $0.06 from a prior closing price of $0.50. However, the script later moved the day high at 0.6000, down -1.34%. The company’s stock has a 5-day price change of -10.02% and -63.34% over the past three months. FNCH shares are trading 3.10% year to date (YTD), with the 12-month market performance down to -94.09% lower. It has a 12-month low price of $0.30 and touched a high of $9.28 over the same period. FNCH has an average intraday trading volume of 84.03K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.69%, -32.38%, and -74.47% respectively.
Institutional ownership of Finch Therapeutics Group Inc. (NASDAQ: FNCH) shares accounts for 21.00% of the company’s 47.73M shares outstanding. Mutual fund holders own 22.70%, while other institutional holders and individual stakeholders account for 3.31% and 14.18% respectively.
It has a market capitalization of $24.50M. The earnings-per-share (ttm) stands at -$2.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.60% over the week and 15.95% over the month.
Analysts forecast that Finch Therapeutics Group Inc. (FNCH) will achieve an EPS of -$0.4 for the current quarter, -$0.32 for the next quarter and -$1.64 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.42 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was -$0.32 a year ago. Earnings per share for the fiscal year are expected to decrease by -77.80%, and 32.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Finch Therapeutics Group Inc. (FNCH) as a “Strong Buy” at a consensus score of 1.70. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the FNCH, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on August 09, 2022, with the firm’s price target at $17. Jefferies coverage for the Finch Therapeutics Group Inc. (FNCH) stock in a research note released on April 13, 2021 offered a Buy rating with a price target of $29. Evercore ISI was of a view on April 13, 2021 that the stock is Outperform, while BofA Securities gave the stock Buy rating on April 13, 2021, issuing a price target of $25.